Want to see SLS full AI Analyst Report?
Top Page
SELLAS Life Sciences Group
(NASDAQ:SLS)
Select Model
Select Model
Rating:54Neutral
Price Target:
$11.50
▼(-18.38% Downside)
Action:Reiterated
Date:08/18/26
The score is held back primarily by weak fundamentals—minimal revenue, persistent losses, and ongoing cash burn—despite a low-debt balance sheet. Technicals are supportive with strong uptrend/momentum, but valuation is constrained by negative earnings and no dividend data. Corporate events are mixed, with improved liquidity offset by dilution and an adverse arbitration ruling.
Positive Factors
Low leverage
Very low debt materially reduces solvency and interest-burden risk while giving the company greater financial flexibility during clinical development. The improved equity position versus 2023 also indicates meaningful balance-sheet repair, supporting continued investment in its pipeline.
Negative Factors
No commercial revenue
The absence of recurring commercial revenue leaves SELLAS dependent on clinical progress and future approvals rather than an established sales engine. This limits operating scale, makes financial performance highly uncertain, and reduces internal funding capacity for ongoing oncology development.
Read all positive and negative factors
Positive Factors
Negative Factors
Low leverage
Very low debt materially reduces solvency and interest-burden risk while giving the company greater financial flexibility during clinical development. The improved equity position versus 2023 also indicates meaningful balance-sheet repair, supporting continued investment in its pipeline.
Read all positive factors
SELLAS Life Sciences Group (SLS) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$2.35B
Dividend YieldN/A
Average Volume (3M)5.91M
Price to Earnings (P/E)―
Beta (1Y)0.64
Revenue GrowthN/A
EPS Growth35.38%
CountryUS
Employees13
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-0.21
Shares Outstanding201,945,710
10 Day Avg. Volume4,600,669
30 Day Avg. Volume5,906,902
Financial Highlights & Ratios
PEG Ratio0.30
Price to Book (P/B)5.80
Price to Sales (P/S)0.00
P/FCF Ratio-14.48
Enterprise Value/Market Cap1.13
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda-104.60
Forecast
1Y Price Target
$30.00Price Target Upside112.92% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)-0.21
Revenue Forecast (FY)$36.13M
SELLAS Life Sciences Group Business Overview & Revenue Model
Company Description
SELLAS Life Sciences Group, Inc., a late-stage clinical biopharmaceutical company, focuses on the development of novel therapeutics for various cancer indications in the United States. The company's lead product candidate is galinpepimut-S (GPS), ...
How the Company Makes Money
As a clinical-stage biotechnology company, SELLAS has historically not generated meaningful recurring revenue from commercial product sales because its lead product candidates are still in clinical development and not broadly approved/marketed. It...
SELLAS Life Sciences Group Financial Statement Overview
Summary
Income Statement
12
Very Negative
Balance Sheet
46
Neutral
Cash Flow
18
Very Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 1.00M | 7.60M |
| Gross Profit | 0.00 | 0.00 | 0.00 | 0.00 | 900.00K | 7.40M |
| EBITDA | -25.38M | -26.86M | 632.00K | 529.00K | -31.49M | -18.32M |
| Net Income | -32.46M | -26.86M | -30.88M | -37.34M | -41.30M | -20.70M |
Balance Sheet | ||||||
| Total Assets | 145.38M | 78.34M | 19.43M | 6.22M | 20.94M | 26.43M |
| Cash, Cash Equivalents and Short-Term Investments | 138.44M | 71.89M | 13.89M | 2.53M | 17.13M | 21.45M |
| Total Debt | 737.00K | 1.00M | 1.00M | 906.00K | 945.00K | 808.00K |
| Total Liabilities | 7.73M | 7.47M | 9.97M | 14.20M | 16.09M | 6.08M |
| Stockholders Equity | 137.66M | 70.87M | 9.46M | -7.98M | 4.85M | 20.35M |
Cash Flow | ||||||
| Free Cash Flow | -28.42M | -28.39M | -35.40M | -36.91M | -28.31M | -26.02M |
| Operating Cash Flow | -28.42M | -28.39M | -35.40M | -31.41M | -23.81M | -26.02M |
| Investing Cash Flow | 0.00 | 0.00 | 0.00 | -5.50M | -4.50M | 0.00 |
| Financing Cash Flow | 141.47M | 86.30M | 46.76M | 22.32M | 24.08M | 12.07M |
SELLAS Life Sciences Group Technical Analysis
Positive
14.09
Price Trends
12.40
Negative
11.41
Positive
8.01
Positive
Market Momentum
-0.30
Negative
47.32
Neutral
31.96
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SLS, the sentiment is Positive. The current price of 14.09 is above the 20-day moving average (MA) of 11.59, above the 50-day MA of 12.40, and above the 200-day MA of 8.01, indicating a neutral trend. The MACD of -0.30 indicates Negative momentum. The RSI at 47.32 is Neutral, neither overbought nor oversold. The STOCH value of 31.96 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for SLS.
SELLAS Life Sciences Group Risk Analysis
SELLAS Life Sciences Group disclosed 77 risk factors in its most recent earnings report. SELLAS Life Sciences Group reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
SELLAS Life Sciences Group Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
64 Neutral | $6.62B | -20.03 | -40.51% | ― | 34.52% | 41.20% | |
62 Neutral | $499.55M | 40.21 | 1.91% | ― | -15.05% | ― | |
57 Neutral | $1.83B | -11.35 | -28.66% | ― | -28.56% | 10.25% | |
54 Neutral | $2.35B | -55.13 | -35.91% | ― | ― | 35.38% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
51 Neutral | $1.24B | -8.88 | -35.35% | ― | ― | 28.64% | |
42 Neutral | $1.21B | -19.31 | 89.71% | ― | ― | ― |
* Healthcare Sector Average
SLS
SELLAS Life Sciences Group
11.65
9.65
482.50%
XNCR
Xencor
24.63
10.67
76.43%
IOVA
Iovance Biotherapeutics
14.62
12.48
583.18%
ARVN
Arvinas Holding Company
7.64
-2.16
-22.04%
ORIC
Oric Pharmaceuticals
11.99
-1.92
-13.80%
NBTX
Nanobiotix
23.68
-6.63
-21.87%
SELLAS Life Sciences Group Corporate Events
Business Operations and StrategyLegal Proceedings
SELLAS Life Sciences Faces Adverse Arbitration Ruling
Negative
Jul 27, 2026
On July 24, 2026, a sole arbitrator at the Hong Kong International Arbitration Centre dismissed SELLAS Life Sciences Group’s claims in a binding arbitration against 3D Medicines, Inc., and ordered SELLAS to pay about $1.0 million of 3D Medic...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.